Valneva: mixed new data in Covid-19

(CercleFinance.com) - Late last week Valneva released new mixed data from a small exploratory study of its inactivated Covid-19 vaccine, VLA2001, as a heterologous booster.


According to the.data, a booster dose was well tolerated in participants who have been previously vaccinated with Pfizer-BioNTech or Moderna products, confirming the favourable safety profile of VLA2001 with either a homologous or heterologous booster.

In contrast, the French vaccine company reports that, in this study, a booster dose with its product generated only a marginal increase in neutralising antibody response.

Valneva is currently seeking regulatory approval for VLA2001 as a homologous and heterologous booster in people previously vaccinated with AstraZeneca's ChAdOx1-S.


Copyright (c) 2023 CercleFinance.com. All rights reserved.